Floatz logo

FILGRASTIM

Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia

Shenzhen Second People's Hospitalprotein_peptidePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia cohort.

Asset / SponsorPhaseRating
Omacetaxine
Shenzhen Second People's Hospital
Phase 4BB
5-azacytidine
Shenzhen Second People's Hospital
Phase 4BB
Cytosin-Arabinosid
Shenzhen Second People's Hospital
Phase 4BB

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →